Alzheimer's Tau Pathology Linked to Epigenetic Silencing of Oligodendrocyte Genes

Alzheimer's disease is defined by amyloid plaques and tau neurofibrillary tangles, but the molecular mechanisms driving variability in these hallmarks across individuals remain poorly understood. This study investigates whether DNA methylation (DNAm) — a key epigenetic regulator — is associated with specific AD endophenotypes, including both neuropathological measures and biochemical protein levels in the brain.

The team analyzed reduced representation bisulfite sequencing (RRBS) data from temporal cortex (TCX, n=455) and cerebellum (CER, n=191) of 472 neuropathologically confirmed AD donors. A novel method was developed to group individual CpG methylation sites into biologically defined regions (rCpGm) using the Roadmap Epigenomics 15-chromatin state model specific to human temporal lobe tissue. This approach captures functional methylation variation more meaningfully than post-hoc statistical groupings. Endophenotypes tested included Braak stage, Thal phase, CAA scores, and biochemical measures of APOE, Aβ40, Aβ42, total tau, and phospho-tau (pTau) across three tissue fractions (soluble, membrane-bound, insoluble).

The EWAS identified 5,478 significant rCpGm associations, and remarkably, 99.7% were associated with tau biochemical measures rather than amyloid or neuropathologic staging. Ninety-three of these associations were concordantly replicated in external datasets. Transcriptome-methylome integration highlighted 535 genes enriched in oligodendrocyte and myelin-related pathways, including the established AD risk gene BIN1, the myelination regulators MYRF, MBP, and MAG, and the novel candidate LDB3. These findings were further validated in independent AD cohorts and primary tauopathy datasets, reinforcing tau — not amyloid — as the primary epigenetic driver.

The biological implication is significant: oligodendrocytes, which produce myelin and support axonal integrity, appear to be epigenetically perturbed in parallel with tau accumulation across multiple tauopathies. This suggests a shared pathomechanism whereby tau buildup disrupts DNAm regulation of oligodendrocyte gene networks, potentially compromising white matter integrity and accelerating neurodegeneration. The authors made all findings publicly accessible through an interactive Multiomic Atlas web application.

Important caveats include the bulk tissue nature of the RRBS data, which blends signals across cell types and may obscure cell-type-specific effects. The study is also cross-sectional in design, limiting causal inference about whether DNAm changes precede or follow tau accumulation.